

BIOMARIN PHARMACEUTICAL INC
 Form 4
 June 05, 2007

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
 Expires: January 31, 2005
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
BIENAIME JEAN JACQUES

(Last) (First) (Middle)

C/O BIOMARIN
 PHARMACEUTICAL INC., 105
 DIGITAL DRIVE

(Street)

NOVATO, CA 94949

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOMARIN PHARMACEUTICAL INC [BMRN]

3. Date of Earliest Transaction
 (Month/Day/Year)
06/01/2007

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director 10% Owner
 Officer (give title below) Other (specify below)
Chief Executive Officer

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
				Code	V	Amount or Price			
Common Stock	06/01/2007 ⁽¹⁾	06/01/2007	M		10,000	A \$ 6.46	25,695	D	
Common Stock	06/01/2007 ⁽¹⁾	06/01/2007	S		100	D \$ 18.18	25,595	D	
Common Stock	06/01/2007 ⁽¹⁾	06/01/2007	S		900	D \$ 18.181	24,695	D	
Common Stock	06/01/2007 ⁽¹⁾	06/01/2007	S		400	D \$ 18.251	24,295	D	
	06/01/2007 ⁽¹⁾	06/01/2007	S		700	D \$ 18.26	23,595	D	

Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 4

Common Stock								
Common Stock	06/01/2007 ⁽¹⁾	06/01/2007	S	900	D	\$ 18.261	22,695	D
Common Stock	06/01/2007 ⁽¹⁾	06/01/2007	S	1,000	D	\$ 18.33	21,695	D
Common Stock	06/01/2007 ⁽¹⁾	06/01/2007	S	200	D	\$ 18.35	21,495	D
Common Stock	06/01/2007 ⁽¹⁾	06/01/2007	S	1,800	D	\$ 18.351	19,695	D
Common Stock	06/01/2007 ⁽¹⁾	06/01/2007	S	100	D	\$ 18.37	19,595	D
Common Stock	06/01/2007 ⁽¹⁾	06/01/2007	S	900	D	\$ 18.371	18,695	D
Common Stock	06/04/2007 ⁽¹⁾	06/04/2007	S	1,800	D	\$ 18.38	16,895	D
Common Stock	06/01/2007 ⁽¹⁾	06/01/2007	S	900	D	\$ 18.381	15,995	D
Common Stock	06/04/2007 ⁽¹⁾	06/04/2007	S	200	D	\$ 18.39	15,795	D
Common Stock	06/01/2007 ⁽¹⁾	06/01/2007	S	700	D	\$ 18.4	15,095	D
Common Stock	06/01/2007 ⁽¹⁾	06/01/2007	S	300	D	\$ 18.401	14,795	D
Common Stock	06/01/2007 ⁽¹⁾	06/01/2007	S	100	D	\$ 18.41	14,695	D
Common Stock	06/01/2007 ⁽¹⁾	06/01/2007	S	900	D	\$ 18.411	13,795	D
Common Stock	06/01/2007 ⁽¹⁾	06/01/2007	S	100	D	\$ 18.38	13,695	D
Common Stock	06/04/2007 ⁽¹⁾	06/04/2007	S	500	D	\$ 18.4	13,195	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)
Stock Option (Right to Buy)	\$ 6.46	06/01/2007 ⁽¹⁾	06/01/2007	M	10,000	05/11/2006 ⁽²⁾ 05/10/2015	Common Stock 10,000

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
BIENAIME JEAN JACQUES C/O BIOMARIN PHARMACEUTICAL INC. 105 DIGITAL DRIVE NOVATO, CA 94949	X		Chief Executive Officer	

Signatures

/s/ G. Eric Davis,
Attorney-in-Fact

06/05/2007

Date

**Signature of Reporting Person

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- (1) Transaction made pursuant to a Rule 10b5-1 Trading Plan.
- (2) Options vest 1/3 each on May 11, 2006, May 11, 2007, and May 11, 2008.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.